Submitted by jwr@option4.com on Sat, 07/17/2010 - 21:11
Eribulin versus Treatment of Physician's Choice for Patients with Heavily Pretreated Advanced Breast Cancer
| CME test | Downloadable PDF | PowerPoint slides | CME Information and Faculty Disclosures |
| Read Dr Love's original email (from July 20, 2010) | Subscribe to Dr Love's email alerts | ||
Slides from a presentation at ASCO 2010 and transcribed comments from recent interviews with Adam M Brufsky, MD, PhD (6/18/10) and Linda T Vahdat, MD (6/5/10)
Twelves C et al. A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician’s choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane. Proc ASCO 2010;Abstract CRA1004.